Accéder au contenu
Merck

High amounts of 17-methylated anabolic-androgenic steroids in effervescent tablets on the dietary supplement market.

Biomedical chromatography : BMC (2006-12-06)
Maria K Parr, Hans Geyer, Bernhard Hoffmann, Karsten Köhler, Ute Mareck, Wilhelm Schänzer
RÉSUMÉ

In numerous studies it has been demonstrated that several nutritional supplements contain prohormones not declared on the label. In the current study two products (effervescent tablets) containing high amounts of the 17-methylated anabolic androgenic steroids metandienone (product 1: 16.8 mg/tablet) and stanozolol (product 2: 14.5 mg/tablet) were identified. Additionally in both products norandrostenedione was detected, in product 2 with minor amounts of several other steroids. The substances identified can cause enormous health risks. In addition, the use of the analyzed tablets can lead to positive doping results for metabolites of the respective steroids in sports. This study again shows the insufficient surveillance of the production and trade of dietary supplements. Consumers should be aware of the enormous health and doping risks connected with the use of such products. For GC-MS identification of the analytes the trimethylsilyl derivatives of the steroids and the mixed N-t-butyldimethylsilyl,O-trimethylsilyl derivatives were used. The quantitation of metandienone, norandrostenedione, and stanozolol was performed using HPLC-DAD.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Methandienone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
17β-Hydroxy-17-methylandrosta-1,4-dien-3-one, analytical standard